First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
19.54
+1.72 (9.65%)
At close: May 8, 2026, 4:00 PM EDT
18.12
-1.42 (-7.27%)
After-hours: May 8, 2026, 5:54 PM EDT
Company Description
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases.
First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026.
First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California.
First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
First Tracks Biotherapeutics, Inc.
| Country | United States |
| Founded | 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Daniel Faga |
Contact Details
Address: 10770 Wateridge Circle, Suite 210 San Diego, California 92121 United States |
Stock Details
| Ticker Symbol | TRAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US3371851029 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Faga | Chief Executive Officer, President and Director |
| Dennis M. Mulroy | Chief Financial Officer |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Benjamin Stone | Chief Business Officer |
| Eric J. Loumeau | Secretary |